******Sanofi Dynavax Deal & Berenberg M&A Push** [developing]** [developing]** [developing]
Key Questions
What is the focus of Sanofi's deal with Dynavax?
The deal highlights Sanofi's Hepatitis B vaccine efforts. It underscores potential strategic moves in vaccines amid ongoing developments.
What does Berenberg recommend for Sanofi's acquisition strategy?
Berenberg calls for more acquisitions to offset recent pipeline failures, citing Sanofi's €25B M&A capacity and €2.3B bond issuance. The firm has updated its earnings estimates accordingly.
How could the Dynavax deal impact Sanofi stock?
The deal represents a potential near-term catalyst, possibly driving multi-week price swings through deal accretion and increased trading volume.
Sanofi deal with Dynavax spotlights Hep B vaccine; Berenberg calls for more acquisitions to offset pipeline flops, updates estimates amid €25B M&A capacity/€2.3B bond. Potential near-term catalyst for multi-week price swings on deal accretion, volume.
Sources (2)
Updated May 13, 2026